IVIVC concepts MCQs With Answer

Introduction: IVIVC concepts MCQs With Answer is designed for M. Pharm students preparing for Advanced Biopharmaceutics & Pharmacokinetics (MPH 202T). This focused quiz set reinforces core concepts of in vitro–in vivo correlation (IVIVC), including levels of IVIVC, deconvolution and convolution techniques, regulatory considerations, discriminatory dissolution, mathematical modeling approaches, and practical aspects for extended-release formulation development. Questions target conceptual understanding and application to formulation and biopharmaceutic problems, helping students evaluate dissolution–absorption relationships, select appropriate IVIVC strategies, interpret validation metrics, and appreciate limitations of various methods. Use these MCQs to deepen knowledge and prepare for exams and research tasks.

Q1. What is the fundamental objective of establishing an in vitro–in vivo correlation (IVIVC)?

• To predict clinical efficacy directly from physicochemical properties
• To correlate an in vitro dissolution profile with an in vivo pharmacokinetic response
• To replace the need for any in vivo studies regardless of formulation type
• To determine toxicological endpoints from dissolution data

Correct Answer: To correlate an in vitro dissolution profile with an in vivo pharmacokinetic response

Q2. Which IVIVC level provides a point-to-point relationship between in vitro dissolution and the in vivo input rate (fraction absorbed) for every time point?

• Level C IVIVC
• Level B IVIVC
• Level A IVIVC
• Level D IVIVC

Correct Answer: Level A IVIVC

Q3. Which deconvolution method is most appropriate for drugs that follow apparent one-compartment kinetics?

• Loo–Riegelman method
• Wagner–Nelson method
• Numerical convolution
• Moment analysis

Correct Answer: Wagner–Nelson method

Q4. The Loo–Riegelman deconvolution method is specifically used when the drug follows which type of pharmacokinetic behavior?

• Zero-order absorption
• Apparent two-compartment kinetics after intravenous administration
• Michaelis–Menten elimination only
• Flip-flop kinetics exclusively

Correct Answer: Apparent two-compartment kinetics after intravenous administration

Q5. Which statement best describes Level B IVIVC?

• It is a single-point correlation using one in vitro time point and one in vivo parameter
• It is a rank-order correlation using statistical moments such as mean residence time or mean dissolution time
• It is a point-to-point prediction of plasma concentration–time profiles
• It directly estimates bioavailability without need for clinical data

Correct Answer: It is a rank-order correlation using statistical moments such as mean residence time or mean dissolution time

Q6. Which in vitro metric is commonly correlated with the fraction of drug absorbed in an IVIVC study?

• Drug melting point
• Fraction dissolved from the dosage form
• Tablet hardness
• Excipient moisture content

Correct Answer: Fraction dissolved from the dosage form

Q7. In IVIVC development, what is the primary purpose of deconvolution?

• To obtain the in vivo input rate (fraction absorbed) from observed plasma concentrations
• To convert dissolution data into particle size distribution
• To identify impurities in the formulation
• To calculate the formulation’s compressibility index

Correct Answer: To obtain the in vivo input rate (fraction absorbed) from observed plasma concentrations

Q8. Which approach is described as model-independent deconvolution?

• Using Wagner–Nelson for all kinetics
• Numerical deconvolution based on observed plasma profiles and IV disposition function
• Fitting a single-compartment model to in vitro data
• Applying Loo–Riegelman to every dataset

Correct Answer: Numerical deconvolution based on observed plasma profiles and IV disposition function

Q9. For extended-release oral products, IVIVC is most successful when absorption is:

• Permeability-limited
• Dissolution-rate-limited
• Completely first-pass metabolism-limited
• Rapid and complete within minutes

Correct Answer: Dissolution-rate-limited

Q10. Which of the following is a key regulatory advantage of a validated Level A IVIVC?

• Automatic approval of all future dose strengths without any data
• Potential reduction of in vivo bioavailability/bioequivalence studies for certain post-approval changes
• Elimination of the need for stability testing
• Ability to waive all clinical safety assessments

Correct Answer: Potential reduction of in vivo bioavailability/bioequivalence studies for certain post-approval changes

Q11. What does the similarity factor f2 measure in dissolution comparisons?

• The absolute dissolution rate constant
• The similarity between two dissolution profiles, where values 50–100 typically indicate sameness
• The permeability of drug across intestinal mucosa
• The dissolution efficiency normalized by tablet weight

Correct Answer: The similarity between two dissolution profiles, where values 50–100 typically indicate sameness

Q12. Which statement about convolution in IVIVC context is correct?

• Convolution derives the fraction absorbed from the in vivo plasma curve
• Convolution uses the in vivo absorption profile and IV disposition to simulate plasma concentrations from in vitro dissolution
• Convolution is only used for intravenous bolus studies
• Convolution refers to aggregation of dissolution curves from multiple batches

Correct Answer: Convolution uses the in vivo absorption profile and IV disposition to simulate plasma concentrations from in vitro dissolution

Q13. Which dissolution test characteristic is most critical to ensure a discriminatory in vitro method for IVIVC?

• It gives identical profiles for all formulations
• It can detect formulation changes that affect in vivo performance
• It always operates at the lowest possible agitation speed
• It uses the most expensive apparatus available

Correct Answer: It can detect formulation changes that affect in vivo performance

Q14. Wagner–Nelson and Loo–Riegelman methods assume which aspect about drug disposition for deconvolution?

• Drug disposition can be described by a known compartmental model
• Drug binds irreversibly to plasma proteins
• Absorption is zero-order only
• Elimination occurs only after complete absorption

Correct Answer: Drug disposition can be described by a known compartmental model

Q15. In IVIVC validation, which PK parameters are commonly used to assess predictive performance?

• Melting point and log P
• Cmax and AUC
• Tablet friability and disintegration time
• Volume of distribution and half-life only

Correct Answer: Cmax and AUC

Q16. Which scenario would most likely invalidate a simple IVIVC between dissolution and absorption?

• The drug shows linear kinetics and dissolution is rate-limiting
• Significant intestinal metabolism or first‑pass extraction that varies with time
• The formulation has controlled release characteristics and consistent in vitro method
• Sink conditions are maintained during dissolution testing

Correct Answer: Significant intestinal metabolism or first‑pass extraction that varies with time

Q17. What is the role of model-dependent IVIVC approaches?

• To numerically invert plasma curves without assumptions
• To fit a specific compartmental absorption/disposition model to describe and predict the in vivo behavior
• To directly measure fraction absorbed in vitro
• To replace analytical method validation

Correct Answer: To fit a specific compartmental absorption/disposition model to describe and predict the in vivo behavior

Q18. Which practical in vitro condition is essential to avoid misleading dissolution results for poorly soluble drugs in IVIVC studies?

• Performing dissolution in pure water without surfactant regardless of solubility
• Maintaining sink conditions using appropriate volume or solubilizing agents
• Using the smallest possible dissolution medium to speed dissolution
• Testing at temperatures well below physiological conditions

Correct Answer: Maintaining sink conditions using appropriate volume or solubilizing agents

Q19. External validation of an IVIVC typically requires which of the following?

• Using the same dataset that built the IVIVC
• Predicting in vivo profiles for an independent formulation or batch not used in model development
• Only in vitro dissolution comparison is sufficient
• Replacement of clinical endpoints with dissolution alone

Correct Answer: Predicting in vivo profiles for an independent formulation or batch not used in model development

Q20. Which factor increases the likelihood of successfully developing an IVIVC for an extended‑release product?

• The product’s absorption is rapid and complete before dissolution becomes relevant
• The drug’s in vivo absorption rate is controlled primarily by dissolution from the formulation
• The formulation shows extreme batch-to-batch variability in release
• The drug is unstable in gastrointestinal fluids

Correct Answer: The drug’s in vivo absorption rate is controlled primarily by dissolution from the formulation

Download